非小细胞肺癌中窖蛋白1和pERK1／2表达与预后相关性研究  

Relationship between expression of caveolin-1 and pERK1/2 and prognosis in non-small cell lung cancer

作　　者：刘宏侠[1] 邢凌霄[2] 汪宏斌[3] 杨俊泉[3] 孙玉满[1] 

机构地区：[1]唐山市协和医院病理科,河北省063000 [2]河北医科大学病理学研究室 [3]唐山市人民医院放化科

出　　处：《中华病理学杂志》2008年第9期615-619,共5页Chinese Journal of Pathology

摘　　要：目的探讨非小细胞肺癌（NSCLC）组织窖蛋白1与pERK1／2的表达及其与预后的关系。方法应用免疫组织化学（SP法）检测160例NSCLC及20例正常肺组织标本中窖蛋白1与pERK1／2的表达。结果窖蛋白1在NSCLC和正常肺组织阳性率分别为65．6％（105／160）和100％（20／20），P=0.002。中一高分化组和低分化组阳性率分别为56．8％（46／81）和75.7％（53／70），P=0．015；Ⅰ-Ⅱ期阳性率为58．2％（53／91），Ⅲ～Ⅳ期阳性率75．4％（52／69），P=0．024；有淋巴结转移组阳性率为77．8％（56／72），无淋巴结转移组阳性率为55．7％（49／88），P=0．003。窖蛋白1阳性患者1、3、5年生存率（71.4％、37．1％、17．1％）低于阴性患者（89．1％、69．1％、43.6％），P=0．000。pERK1／2在NSCLC和正常肺组织阳性率分别为61．3％和0，P=0．000；中一高分化组和低分化组阳性率分别为53．1％（43／81）和71．4％（50／70），P=0.021；Ⅰ～Ⅱ期阳性率为49．5％（45／91），Ⅲ-Ⅳ期阳性率76.8％（53／69），P=0．000；有淋巴结转移组阳性率为80．6％（58／72），无淋巴结转移组阳性率为45.5％（40／88），P=0．000。pERK1／2阳性患者1、3、5年生存率（74．5％、42.9％、19．4％）低于阴性者（82．3％、56．5％、37．1％），P=0.002。窖蛋白1与pERK1／2负相关，P=0．000。结论窖蛋白1在NSCLC中低表达，pERK1／2在NSCLC中高表达。窖蛋白1蛋白阳性表达和pERK1／2蛋白高表达与NSCLC的发生及侵袭、转移相关。窖蛋白1和pERK1／2可作为NSCLC一个预后预测的指标。Objective To study the relationship between expression of caveolin-1 （ Cav-1 ） and pERK1/2 and prognosis in non-small cell lung cancer （NSCLC）. Methods Car-1 and pERK1/2 protein expression was assessed by immunohistochemistry in samples obtained from 160 patients with NSCLC and 20 patients with normal lung tissue. Results Normal bronchial and alveolar epithelial cells were positive for Cav-1 （membranous and cytoplasmic staining patterns）. The expression rate of Cav-1 in NSCLC was 65.6% （105/160） , which was significantly lower than that in normal lung tissue （P =0. 002）. The Cav-1-positive rates in well to moderately differentiated tumors and poorly differentiated tumors were 56. 8% （46/81） and 75.7% （53/70） , respectively （P = 0. 015 ）. The expression of Cav-1 was much higher in patients with lymph node metastasis （77.8%, compared with 55.7% in lymph node-negative group,P = 0. 003 ）. The expression was also higher in stage Ⅲ to Ⅵ than in stage Ⅰ to Ⅱ disease （75.4% , compared with 58.2% ,P = 0. 024）. The overall survival of patients with Cav-1-positive tumors （71.4%, 37.1% and 17. 1% 1-, 3-and 5-year survival, respectively） was lower than those with Cav-1-negative tumors （89. 1%, 69. 1% and 43.6% 1-, 3- and 5-year survival, respectively, P = 0. 000 ） . On the other hand, normal bronchial and alveolar epithelial cells were negative for pERK1/2. The expression rate of pERK1/2 in NSCLC was 61.3% , which was significantly higher than that in normal lung tissues （ P = 0. 000 ）. The pERK1/2-positive rates in well to moderately differentiated tumors and poorly differentiated tumors was 53.1% and 71.4%, respectively （P = 0. 021 ）. The expression of pERK1/2 was much higher in patients with lymph node metastasis （ 80. 6%, compared with 45.5% in lymph node-negative group, P = 0. 000）. The expression of pERK1/2 was also higher in stage m to iv than in stage Ⅰ to Ⅱ disease （ 76. 8%, compared with 49.5%, P = 0. 426 ） . The overall survival of patients

关 键 词：癌 非小细胞肺 窖蛋白1 细胞外信号调节MAP激酶类 

分 类 号：R686[医药卫生—骨科学]